The amount of change in fair value of warrant derivative liability.

No definition available.

Name:	rzlt_ChangeInFairValueOfWarrantDerivativeLiability
Namespace Prefix:	rzlt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of milestone payment made during the period.

+ References

No definition available.

+ Details

Name:	rzlt_MilestoneClosingPayment
Namespace Prefix:	rzlt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percentage of stock acquired to the total of outstanding shares.

+ References

No definition available.

+ Details

Name:	rzlt_PercentageOfTreasuryStockAcquiredOfSharesOutstanding
Namespace Prefix:	rzlt_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Fair value as of the balance sheet date of the warrants derivative classified as a liability.

+ References

No definition available.

+ Details

Name:	rzlt_WarrantDerivativeLiabilityNonCurrent
Namespace Prefix:	rzlt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants.

+ References

No definition available.

+ Details

Name:	rzlt_WarrantsExercisableOwnershipBlockerPercentage
Namespace Prefix:	rzlt_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A

+ Details

Name:	us-gaap_GainLossOnDerivativeInstrumentsNetPretax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	rzlt_AgreementAxis=rzlt_SecuritiesExchangeAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=rzlt_ScenarioUponFirstDosingOfFirstPatientMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rzlt_XomaUsLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz358Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rzlt_XomaLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUBSEQUENT EVENTS (Details) - USD ($)			1 Months Ended	3 Months Ended			9 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($)	Apr. 01, 2024	Mar. 08, 2024	May 13, 2024	Jun. 30, 2024	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Subsequent Event [Line Items]
Loss from change in fair value of derivative liabilities					$ (1,959,000)	$ (14,000)	$ (1,991,000)	$ (40,000)
Warrant derivative liability					7,647,000		7,647,000
Securities exchange agreement
Subsequent Event [Line Items]
Outstanding shares percentage		7.00%
Securities exchange agreement \| Exchange Pre-Funded Warrants
Subsequent Event [Line Items]
Warrants exercisable, ownership blocker percentage		9.99%
Outstanding shares percentage		7.00%
Change in fair value of derivative liability					1,950,000		1,950,000
Warrant derivative liability		$ 5,700,000			$ 7,600,000		7,600,000
Scenario, Upon First Dosing Of The First Patient \| XOMA (US) LLC \| Phase 3 Clinical Trial RZ 358 \| Xoma License Agreement
Subsequent Event [Line Items]
Milestone closing payment							$ 5,000,000.0
Maximum \| Securities exchange agreement \| Exchange Pre-Funded Warrants
Subsequent Event [Line Items]
Warrants exercisable, ownership blocker percentage		19.99%
Subsequent Event \| Securities exchange agreement \| Exchange Pre-Funded Warrants
Subsequent Event [Line Items]
Change in fair value of derivative liability			$ 900,000
Loss from change in fair value of derivative liabilities				$ (900,000)
Warrant derivative liability			$ 8,600,000
Subsequent Event \| Scenario, Upon First Dosing Of The First Patient \| XOMA (US) LLC \| Phase 3 Clinical Trial RZ 358 \| Xoma License Agreement
Subsequent Event [Line Items]
Milestone closing payment	$ 5,000,000.0